<DOC>
	<DOCNO>NCT00070148</DOCNO>
	<brief_summary>RATIONALE : Oxandrolone megestrol may help prevent weight loss improve quality life patient cancer . It yet know whether oxandrolone effective megestrol prevent weight loss improve quality life patient receive chemotherapy solid tumor . PURPOSE : This randomized phase III trial study oxandrolone see well work compare megestrol prevent weight loss improve quality life patient receive chemotherapy solid tumor .</brief_summary>
	<brief_title>Oxandrolone Compared With Megestrol Preventing Weight Loss Patients Receiving Chemotherapy Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare lean body mass weight patient solid tumor weight loss receive chemotherapy treat oxandrolone v megestrol . - Compare health-related quality life patient treat drug . OUTLINE : This randomize , multicenter study . Patients stratify accord disease stage ( I-III v IV ) , concurrent radiotherapy ( yes v ) , gender . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral oxandrolone twice daily . - Arm II : Patients receive oral megestrol daily . In arm , treatment continue 12 week absence excessive weight loss gain unacceptable toxicity . Quality life , weight , body composition assess baseline , 1 , 2 , 3 month study therapy , 1 month study completion . Patients follow 1 month . PROJECTED ACCRUAL : A total 62-155 patient ( 31-77 per treatment arm ) accrue study within 2 year .</detailed_description>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Body Weight Changes</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<mesh_term>Oxandrolone</mesh_term>
	<criteria>INCLUSION CRITERIA : Age &gt; 18 year preexist uncontrolled medical psychological illness would impair patient 's ability provide inform consent complete protocol therapy quality life questionnaire . A minimum one month plan chemotherapy remain time Oxandrin Megestrol acetate begin . Oral chemotherapy medication , biologicals , monoclonal antibody include eligibility criterion . Histologically confirm solid tumor ( see exception ineligibility list ) Female patient history breast cancer , gynecologic cancer , hormonally responsive germ cell tumor must disease free &gt; 5 year eligible study Patients nonmelanoma skin cancer carcinoma situ cervix eligible . History weight loss : 1 . &gt; 5 % total body weight previous 6 month OR 2 . &gt; 3 % previous month OR 3 . Progressive weight loss 2 consecutive visit despite attempt dietary , behavioral , pharmacologic intervention . ECOG Performance Status 02 Life expectancy &gt; 6 month Serum creatinine &lt; 2.5mg/dl , SGOT SGPT &lt; 2 time upper limit normal , total bilirubin &lt; 2.5 mg/dl Patients must able swallow 1 tablet twice day 20 cc liquid day Patients must able meet nutritional requirement via oral route food and/or oral supplement via enteral tube feeding . However , Oxandrin pills must administer orally . Patients take warfarin maintenance central venous catheter patency eligible trial INR &lt; 1.2 . Because interaction warfarin Oxandrin , maintenance dose warfarin eligible patient halve keep INR 11.2 . For example , patient take 1 mg warfarin study entry , recommend dose decrease 0.5 mg per day , dose decreased every day , every third day , etc . keep INR &lt; 1.2 . The INR must check weekly stable &lt; 1.2 . Patients receive concurrent RT . EXCLUSION CRITERIA : Ongoing plan treatment corticosteroid medication , estrogen , progestin ( include Megestrol acetate ) steroid hormone study period . Patients receive intermittent corticosteroid part prechemotherapy antiemetic regimen eligible study . Patients treat Oxandrin Megestrol acetate &lt; 3 month study entry eligible . Patients take dronabinol appetite stimulant must medication minimum 3 day prior start study medication . Patients follow ineligible : Prostate cancer Male breast cancer Female breast , gynecologic , hormonally responsive germ cell tumor last 5 year Primary metastatic malignant brain tumor stable demonstrate progressive disease last 6 month . Leukemia , lymphoma , myeloma hematologic malignancy Men &gt; 40 year age prostatespecific antigen ( PSA ) level check monitor past year . Those patient PSA &gt; 4 ng/mL exclude participation study . If require , PSA do within 2 week prior registration . Patients hypercalcemia , nephrosis nephrotic phase nephritis uncontrolled hypertension , congestive heart failure , pulmonary edema , unstable angina Cushing 's syndrome . Patients recent ( within 6 month ) active thromboembolic disease recent myocardial infarction ( within 3 month study entry ) . Systemic anticoagulation : Patients currently oral anticoagulant ( warfarin ) eligible unless take low dos warfarin catheter patency . If patient develop thromboembolic disease treatment , may remain study . It recommend receive standard load dose coumadin day 1. interaction Oxandrin Coumadin ( Oxandrin elevate INR ) , patient subsequently require much low dose Coumadin . The effect combine medication develop within 24 48 hour . The recommended Coumadin dose decrease 20 % normally required sufficient anticoagulation . ( Example : If patient would normally receive 5 mg every day , receive 1 mg every day . ) PT/INR result monitor frequently dosage adjustment need . Significant ascites , pleural effusion edema may inhibit oral food intake invalidate weight determination . Diabetic medication allow , however patient take sulfonyureas ineligible . Below list commonly use sulfonyureas ( Note : This helpful guide , complete list . ) : Glimepiride ( Amaryl® ) , glyburide ( DiaBeta® ) , chlorpropamide ( Diabinese® ) , glipizide ( Glucatrol® ) , combine glyburide metformin ( Glucovance® ) orinase ( Tolbutamide® ) . There contraindication concomitant use insulin oxandrolone ( Oxandrin® ) require patient . Any patient insulin oral hypoglycemics selfmonitor prevent hypo &amp; hyperglycemia . Patients pregnant nursing . Patients history priapism ( persistant erection ) sickle cell anemia . Patients BMI ( Body Mass Index ) ≥ 35</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>weight change</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>